A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese.

Abstract

An association between the Pro/Pro genotype of p53 codon 72 and a lower risk of prostate cancer in Caucasians was recently reported. However, the association of this polymorphism with prostate cancer risk in a Japanese population has not been clarified. We performed a case-control study consisting of 114 prostate cancer patients and 105 noncancer controls. Sixty-nine percent (79 of 114) of the patients had a positive family history. The genotypic frequencies in the controls were 39.0% for Arg/Arg, 54.3% for Arg/Pro and 6.7% for Pro/Pro; they were in Hardy-Weinberg equilibrium. When a comparison of the distribution of the p53 codon 72 polymorphism was made between patients with a first-degree family history and all control subjects, the adjusted odds ratios (ORs) for prostate cancer associated with the Arg/Arg, Arg/Pro and Pro/Pro genotypes were 1.00, 0.99 [95% confidence interval (CI) 0.53-1.88] and 2.80 (95% CI 1.04-7.53), respectively. When stratification of cases was performed based on clinical stage (localized or metastatic cancer) and pathological grade (a Gleason score of <7 or > or =7), there tended to be a greater number of patients with localized cancers among those patients with the Arg/Pro genotype than among those with the Arg/Arg genotype (overall cases: age-adjusted OR 0.36, 95% CI 0.13-1.00, p = 0.049; positive family history cases: age-adjusted OR 0.25, 95% CI 0.075-0.84, p = 0.025). In addition, there tended to be a greater number of patients with low-grade cancers among those with the Pro/Pro genotype than among those with other genotypes (overall cases: age-adjusted OR 0.41, 95% CI 0.13-1.30, p = 0.13; positive family history cases: age-adjusted OR 0.20, 95% CI 0.004-0.89, p = 0.035). The present findings suggest that the Pro/Pro genotype of p53 codon 72 played a role in prostate cancer susceptibility in a Japanese population. However, the Pro allele did not appear to worsen such clinical parameters as clinical stage or pathological grade.

• Authors: Kazuhiro Suzuki, Hiroshi Matsui, Nobuaki Ohtake, Seiji Nakata, Tomoyuki Takei, Haruki Nakazato, Hironobu Okugi, Hidekazu Koike, Yoshihiro Ono, Kazuto Ito, Kohei Kurokawa, Hidetoshi Yamanaka
• Journal: Journal of biomedical science (J Biomed Sci) 2003 Jul-Aug Vol. 10 Issue 4 Pg. 430-5 ISSN: 1021-7770 [Print] England
• PMID: 12824702 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2003 National Science Council, ROC and S. Karger AG, Basel

Chemical References

• Codon
• Tumor Suppressor Protein p53

Topics

• Adult
• Aged
• Asian People
• Case-Control Studies
• Codon
• Disease Progression
• Genes, p53
• Genetic Predisposition to Disease
• Genotype
• Humans
• Male
• Middle Aged
• Polymorphism, Genetic
• Prostatic Neoplasms (genetics, pathology, physiopathology)
• Tumor Suppressor Protein p53
• Urinary Bladder Neoplasms (genetics)